The National Pharmaceutical Pricing Authority updated the maximum retail price for 1,085 anti-cancer medicines. This revision follows a pre...

Mumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for dif...

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicine...

Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth ...

From a pancreatic cancer drug that targets KRAS mutations to a smarter power wheelchair, University of California research is reaching beyo...

Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...

Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...

The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...

India should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method - not a...

Prices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...

India has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...

Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...

In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...

Govt has told Supreme Court that hospitals overcharging patients for medicines and medical consumables is a malpractice. Its affidavit cite...